Table 1.
Clinicopathologic characteristics of the luminal-like MBC cohort.
| Characteristics | No | % |
|---|---|---|
| BC histological type | ||
| NST | 509 | 84.55 |
| Lobular | 93 | 15.45 |
| BC IHC characteristics | ||
| ER + | 697 | 99.15 |
| PR + | 464 | 66.67 |
| HER2+ | 0 | 0 |
| Metastatic involvement | ||
| Bone | 548 | 78.06 |
| Liver | 290 | 41.31 |
| Lymph nodes | 262 | 37.32 |
| Lung | 221 | 31.48 |
| Soft tissue | 125 | 17.81 |
| CNS | 46 | 6.55 |
| Previous treatments | ||
| ET | 452 | 74.10 |
| CT | 257 | 42.13 |
| CDK4/6 inhibitors | 322 | 52.79 |
| mTOR inhibitors | 105 | 17.21 |
| PI3K inhibitors | 38 | 6.23 |
| Immunotherapy | 8 | 1.31 |
NST (Non-Special Type), CNS (Central Nervous System), ET (Endocrine Therapy), CT (Chemotherapy)